For anyone in Bene trying to locate CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. This global online supply model is a genuine benefit for researchers — top vendors differentiate through analytical documentation in ways no local retailer can match. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. Use this guide to verify vendor quality systematically — the framework here work regardless of your location.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Bene researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Where to Buy CJC-1295 — A Researcher's Guide
Before assessing any particular supplier, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. For Bene researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before placing larger orders is standard practice in the community. Bacteriostatic water is the correct reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to 30 days refrigerated.
Order CJC-1295 — ships to Bene
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Temperature excursions — even short periods above −20°C — can cause partial degradation without detectable changes to appearance; always maintain cold chain and work with cold-shipped material. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at trace quantities, and no pricing advantage justifies skipping this verification. Researchers using CJC-1295 alongside other research compounds should check the research literature for any reported interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
